Influenza vaccine quadrivalent - bioCSL

Drug Profile

Influenza vaccine quadrivalent - bioCSL

Alternative Names: CSL QIV; Quadrivalent influenza vaccine - bioCSL; Seqirus QIV

Latest Information Update: 02 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator bioCSL
  • Developer bioCSL; Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 26 Oct 2016 Safety from a phase III trial in Influenza virus infection presented at the IDWeek-2016 (IDWeek-2016)
  • 22 Sep 2016 Seqirus plans a phase III non-inferiority trial for Influenza virus infections (Prevention, In infants, In children) in USA (IM) (NCT02914275)
  • 01 Sep 2016 Phase-III clinical trials in Influenza virus infections (In infants, In children, Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top